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Abstract
Hypertension, a common cardiovascular disease (CVD) risk factor, is usually diagnosed and 
treated based on blood pressure readings obtained in the clinic setting. Blood pressure may differ 
considerably when measured in the clinic versus outside of the clinic setting. Over the past several 
decades, evidence has accumulated on two approaches for measuring out-of-clinic blood pressure: 
ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM). 
Blood pressure measures on ABPM and HBPM each have a stronger association with CVD 
outcomes than clinic blood pressure. Controversy exists whether ABPM or HBPM is superior for 
estimating CVD risk, and under what circumstances these methods should be used in clinical 
practice for assessing out-of-clinic blood pressure. This review describes ABPM and HBPM 
procedures, the blood pressure phenotypic measures that can be ascertained, and the evidence that 
supports the use of each approach to measure out-of-clinic blood pressure. This review also 
describes barriers to the successful implementation of ABPM and HBPM in clinical practice, 
proposes core competencies for the conduct of these procedures, and highlights important areas 
for future research.
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Guidelines and scientific statements recommend measuring blood pressure in the clinic 
setting (1, 2). Blood pressure measured in the clinic may not accurately reflect levels that a 
patient experiences in the out-of-clinic naturalistic setting (3). Ambulatory blood pressure 
monitoring (ABPM) and home blood pressure monitoring (HBPM) are two well-accepted 
approaches for measuring out-of-clinic blood pressure (4, 5).
The utility of ABPM and HBPM in guiding patient care has been widely debated (6, 7), and 
there is controversy about which method is better for determining out-of-clinic blood 
pressure. This review describes ABPM and HBPM procedures, the blood pressure measures 
that can be obtained using these methods, and the current evidence base supporting the use 
of ABPM and HBPM in clinical practice; barriers and clinical competencies that are 
required for the successful implementation of ABPM and HBPM in practice; and areas of 
future research.
Methods
MEDLINE was searched through July 2015 using the following key words: “ambulatory 
blood pressure”, “home blood pressure”, “out of office blood pressure”, “self-measured 
blood pressure”, and “self-measurement of blood pressure”. We focused on studies that had 
prospective follow-up for CVD events and/or mortality; systematic reviews, meta-analyses, 
narrative reviews; and hypertension guidelines, scientific statements, and position papers. A 
PubMed related articles search and a cited reference search through ISI Web of Science 
were conducted using identified articles. A manual search was also performed using the 
reference lists from identified reviews.
Role of the Funding Source
The funding source had no role in the study design, collection, analysis, interpretation, or 
drafting of the manuscript or in the decision to submit the manuscript for publication.
Fundamentals of ABPM and HBPM
Overview of ABPM Procedures
In the 1960’s, a manually inflated device was introduced that could take blood pressure 
readings on an ambulatory basis throughout the day (8). At present, ambulatory monitors are 
fully automated, utilize the oscillometric technique to estimate blood pressure, and are 
typically used to obtain blood pressure readings for a 24-hour period (3). Ambulatory 
monitors are compact, typically worn on a belt or in a pouch, and connected to a 
sphygmomanometer cuff on the upper arm by a tube. The monitors are usually programmed 
to obtain readings every 15 to 30 minutes throughout the day and night, and set without the 
readings being displayed to the patient. Although ABPM occurs while individuals go about 
their normal daily activities, they are asked to keep their arm still while the cuff is inflating, 
and to avoid excessive motion, which is associated with unobtainable or artifactual readings. 
At the end of the recording period, the readings are downloaded into a computer for 
processing. Individuals can fill out a diary during the monitoring period to document any 
symptoms, awakening and sleeping times, naps, periods of stress, timing of meals, and 
medication ingestion (4).
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Various criteria can be used for determining whether a 24-hour ABPM session is valid 
including, for example, a minimum of 70% or 80% of the planned readings are obtained (4, 
9); at least 14 readings are obtained during the daytime period (10); or at least 10 readings 
are obtained during the daytime period and at least 5 readings are obtained during the 
nighttime period (11). None of these criteria are considered to be a gold standard. The 
daytime and nighttime periods on ABPM can be determined by using the patient’s self-
report of awakening and sleeping (4), fixed time periods (4), and actigraphy (12). Herein, 
the terms “daytime” and nighttime” (or “nocturnal”) are used interchangeably with “awake” 
and “sleep”, respectively. Figure 1 (upper panel) shows blood pressure readings obtained 
from an individual in the clinic followed by 24-hour ABPM.
Overview of HBPM Procedures
Home blood pressure was initially measured with the auscultatory technique by an observer 
(13). Most currently available HPBM devices are automatic, utilize the oscillometric 
technique, and are initiated by the patient. Some devices are able to store readings for 
several weeks, which minimize the need for patients to record the measurements. HBPM 
devices, which measure blood pressure in the brachial artery, are more reliable than other 
types of devices such as wrist monitors (13). HBPM should be performed in a quiet room 
after 5 minutes of rest in the seated position, with the back and arm supported. A common 
recommendation for HBPM (2, 5, 14) is that blood pressure be measured by the patient 2 
times in the morning and 2 times in the evening. A minimum of 3 consecutive days and a 
preferred period of 7 consecutive days of HBPM is a reasonable approach for clinical 
practice (2, 5, 14). For assessing mean blood pressure, readings obtained on the first day of 
HBPM are excluded, and all subsequent readings across days are averaged (2, 5, 14). Figure 
1 (lower panel) shows blood pressure readings from HBPM for the same individual in the 
upper panel who underwent HBPM after ABPM.
Validated Devices
Only validated devices are recommended for conducting ABPM and HBPM. Three 
validation protocols are widely accepted: the Association for the Advancement of Medical 
Instrumentation (AAMI) (15), the British Hypertension Society (BHS) (16), and the ESH 
International Protocol (ESH-IP) (17). The 2010 ESH-IP (17) is currently the most 
commonly used. An up-to-date list of validated ambulatory and home blood pressure 
monitors is available on the dabl Educational Trust website (www.dableducational.org) (18), 
and also the British Hypertension Society website (http://www.bhsoc.org/bp-monitors/bp-
monitors) (19).
Similarities and Differences in Performing ABPM and HBPM
More measurements are typically obtained with ABPM and HBPM than in the clinic setting. 
ABPM and HBPM can assess average blood pressure outside of the clinic setting, which 
allows for the identification of white coat hypertension (20, 21) and masked hypertension 
(22-24); blood pressure variability on ABPM (25) and HBPM (26); and hypotension (2, 4). 
As ABPM and HBPM devices use the oscillometric technique, which assesses the amplitude 
of pressure oscillations during cuff deflation to estimate blood pressure, accurate 
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measurements can be affected by movement (27). The ability to obtain accurate readings is 
also limited by larger upper arm circumference, arterial stiffness, and variability in heart rate 
(e.g. atrial fibrillation) (27). As ABPM and HBPM devices inflate the blood pressure cuff 
above systolic blood pressure, individuals particularly with severe hypertension may 
experience discomfort or pain with repeated measurements. The main difference between 
ABPM and HBPM is that ABPM assesses daytime and nighttime blood pressure during 
routine daily activities typically during one 24-hour period, whereas HBPM assesses blood 
pressure at specific times during the day and night over a longer period of time while the 
patient is seated and resting. For almost all HBPM devices, blood pressure readings cannot 
be obtained during sleep.
Clinical Significance
Elevated blood pressure on ABPM and HBPM
Numerous studies have reported associations of average out-of-clinic blood pressure 
measured by ABPM including average 24-hour, daytime and nighttime blood pressure, and, 
separately, average blood pressure on HBPM with CVD and mortality outcomes, 
independent of mean clinic blood pressure (28-32). Few studies with CVD events or 
mortality as outcomes have conducted both ABPM and HBPM in the same sample (33-36), 
and it remains unclear which method is superior for predicting outcomes. Levels that 
constitute normality and elevated blood pressure status for ABPM and HBPM have been 
published (1, 2, 4, 5, 37-39) (Table 1). Most of the normality data for ABPM and HBPM 
have been derived from studies conducted in Europe and Japan.
Phenotypes defined by clinic and out-of-clinic hypertension status
Four phenotypes can be defined by cross-classifying clinic and out-of-clinic hypertension 
status using ABPM or HBPM (Table 2). Two phenotypes represent agreement; sustained 
normotension (non-elevated clinic and non-elevated out-of-clinic blood pressure) and 
sustained hypertension (elevated clinic and elevated out-of-clinic blood pressure), which are 
phenotypes associated with the lowest and highest CVD risk, respectively (40). As 
originally described by Pickering (20), the term “white coat hypertension” refers to 
untreated individuals with elevated clinic blood pressure without elevated daytime blood 
pressure on ABPM. The term “masked hypertension” refers to untreated individuals who do 
not have elevated clinic blood pressure but have elevated daytime blood pressure on ABPM 
(22). In addition to those with daytime hypertension, individuals without elevated clinic 
blood pressure but with 24-hour hypertension and/or nighttime hypertension are also 
considered to have masked hypertension (4). HBPM can also be used to define white coat 
hypertension and masked hypertension (5).
The terms white coat hypertension and masked hypertension can be applied to individuals 
taking antihypertensive medication (23, 41). Treated individuals with elevated clinic blood 
pressure without elevated out-of-clinic blood pressure have “treated white coat 
hypertension” or “white coat uncontrolled hypertension”, and treated individuals with non-
elevated clinic blood pressure with elevated out-of-clinic blood pressure have “treated 
masked hypertension” or “masked uncontrolled hypertension”. ABPM and HBPM can 
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identify white coat resistant hypertension (42, 43), which is defined as treatment resistant 
hypertension based on clinic blood pressure but controlled out-of-clinic blood pressure. In 
untreated and treated individuals, ABPM and HBPM can assess the white coat effect, 
defined as having a clinic blood pressure that is greater than average out-of-clinic blood 
pressure, and the masked hypertensive effect, defined as having an average out-of-clinic 
blood pressure that is greater than clinic blood pressure.
White coat hypertension—A systematic review performed for the United States 
Preventive Services Task Force (USPSTF) evaluated the prevalence of white coat 
hypertension using ABPM and HBPM in untreated populations (28). Across 22 studies of 
ABPM, the prevalence of white coat hypertension ranged from 5% to 65%. The prevalence 
of white coat hypertension ranged from 16% to 55% across six studies using HBPM. Several 
(21, 28, 41, 44, 45), but not all (46, 47) studies have reported white coat hypertension to not 
be associated with an increased risk for CVD outcomes, compared to sustained 
normotension. Treated white coat hypertension has not been associated with an increased 
risk of CVD events or mortality, compared with treated sustained normotension (21, 41, 47).
Masked hypertension—In a systematic review which identified 5 population-based 
studies (four conducted in Europe and one in Japan), the prevalence of masked hypertension 
ranged from 14% to 30% among participants without elevated clinic blood pressure (23). 
Three of the studies used ABPM only (48-50), one used HBPM only (51), and one used both 
ABPM and HBPM (46). Four studies included participants on antihypertensive medication 
(46, 49-51). In addition to being associated with subclinical CVD (52), masked hypertension 
is associated with an increased risk of CVD events. In a meta-analysis of 7 studies 
(n=11,502; 5 studies with ABPM and 2 studies with HBPM, 6 studies included treated 
participants) (53), the multivariable adjusted hazard ratio (HR) for CVD events, comparing 
masked hypertension to sustained normotension was 2.00 (95% CI: 1.58–2.52). These 
findings are similar to results from a second meta-analysis of individual-level data from four 
population samples of ABPM (n=7,030; 21.8% were taking antihypertensive medications) 
(30), and a study of untreated individuals undergoing HBPM (47). Among individuals 
taking antihypertensive medication, treated masked hypertension on ABPM or HBPM has 
been associated with an increased risk of CVD events and mortality compared with 
sustained normotension (24, 47).
Other Measures and Phenotypes that ABPM or HBPM Captures
Non-dipping blood pressure and nocturnal hypertension
There is a diurnal pattern of blood pressure (54), which normally falls to its lowest level 
during nighttime hours (Figure 1, top panel). Some individuals do not experience a normal 
decline in blood pressure at night, and those whose blood pressure does not decline between 
daytime and nighttime by 10% or more on ABPM are considered non-dippers (2, 4). 
Individuals can have nocturnal hypertension, which is commonly defined as mean nighttime 
SBP/DBP ≥ 120/70 mm Hg (55). Several studies have reported that non-dipping blood 
pressure and nocturnal hypertension are associated with increased risk for CVD events and 
all-cause mortality, independent of clinic and daytime blood pressure (31, 56).
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The morning surge refers to the increase in blood pressure that normally occurs from the 
nighttime to the early morning (Figure 1). This time period corresponds to the time during 
which the incidence of CVD events are increased (57). Some studies have identified an 
association between an exaggerated morning surge on ABPM and increased stroke risk (57).
Blood pressure variability
Blood pressure variability on 24-hour ABPM is generally reported using two metrics, day-
night standard deviation which captures the variability a patient experiences around their 
mean daytime and nighttime blood pressure, and average real variability which captures 
variability in blood pressure between successive measurements (58, 59). Although 24-hour 
blood pressure variability using these metrics was associated with an increased risk for CVD 
events and mortality in a meta-analysis (25), the clinical applicability of blood pressure 
variability may be limited given its relatively low reproducibility (60) and a modest increase 
in absolute CVD risk (25). HBPM can be used to capture long-term (day-to-day) blood 
pressure variability. In a systematic review (26), higher day-to-day blood pressure variability 
was associated with an increased risk of CVD events and/or mortality.
Hypotension
ABPM or HBPM can be used to assess postural hypotension, postprandial hypotension, 
drug-induced hypotension, and hypotension from autonomic dysfunction (4). Either 
approach can also be used to evaluate syncope, vertigo, or dizziness (61, 62). Although 
ABPM and HBPM only provide intermittent BP measurements, they offer the ability to 
obtain measurements at a time when a patient is symptomatic. ABPM can be combined with 
Holter monitoring for simultaneous recording of blood pressure and the electrocardiogram to 
evaluate hypotension or symptoms (4).
Clinical Indications for Using ABPM and HBPM
Guidelines, scientific statements, and position papers most commonly recommend ABPM to 
exclude white coat hypertension in individuals with elevated clinic blood pressure 
(Appendix Table 1, available at www.annals.org). In a recent draft statement from the 
USPSTF (63), ABPM was endorsed for confirming the diagnosis of hypertension and 
excluding white coat hypertension, except in patients for which immediate treatment 
initiation may be indicated including SBP/DBP ≥180/110 mm Hg, evidence of end-organ 
damage, and/or those with a diagnosis of secondary hypertension. Other indications for 
ABPM include the monitoring of antihypertensive medication efficacy in treated 
hypertensive patients who have elevated clinic blood pressure in order to determine blood 
pressure control over the course of the day. Less common recommendations include the 
assessment of masked hypertension, treated masked hypertension, diurnal blood pressure 
patterns, 24-hour blood pressure variability, and hypotension. HBPM is not recommended as 
often as ABPM (Appendix Table 2, available at www.annals.org). HBPM is most 
commonly recommended for diagnosing white coat hypertension or assessing treatment 
resistant hypertension. The draft statement from USPSTF (63) did not officially endorse 
using HBPM to exclude white coat hypertension, but did state that the “confirmation of 
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hypertension using HBPM may be acceptable.” For clinical practice, it is reasonable that 
out-of-clinic blood pressure monitoring be primarily undertaken using ABPM to rule out 
white coat hypertension in individuals with elevated clinic blood pressure. HBPM can be 
performed if ABPM is not available or poorly tolerated by the patient. In the clinic, 
automatic blood pressure devices are preferred over manual devices, given the closer 
agreement between clinic and out-of-clinic blood pressure levels (64). For patients taking 
antihypertensive medication, ABPM and secondarily HBPM are sometimes performed for 
the assessment of treated white coat hypertension, the white coat effect, and the 
determination of whether out-of-clinic blood pressure is controlled in patients with treatment 
resistant hypertension based on clinic blood pressure. ABPM and HBPM could be used for 
the assessment of treated masked hypertension and the masked hypertensive effect. Use of 
ABPM and HBPM in these situations should be weighed in context with the large body of 
evidence supporting the cardiovascular benefits of antihypertensive treatment using clinic 
blood pressure thresholds to guide therapy (2). The evidence supporting the achievement of 
blood pressure goals using ABPM or HBPM compared with targeting a clinic blood pressure 
goal on reducing CVD events and mortality is limited.
Challenges in using ABPM and HBPM in Clinical Practice
ABPM is not widely available in primary care settings and is generally only offered in 
specialized hypertension centers (65, 66). Insurance companies do not commonly reimburse 
for indications other than white coat hypertension. Also, the amount of reimbursement for 
ABPM is low (4, 67). Some patients may have difficulty wearing ABPM devices at night 
(68). There is also lack of formal training or certification for ABPM that may make it 
difficult for physicians set up these services in their practices.
In contrast to ABPM, HBPM devices are more widely available. Other advantages for using 
HBPM rather than ABPM include potentially greater patient acceptability and tolerability, 
and better reproducibility of blood pressure phenotypes (5, 13, 39, 69). HBPM may also be 
associated with an improvement in antihypertensive medication adherence (70). However, 
many devices are being sold that have not been validated (71). Further, although cheaper 
than ABPM devices, the cost of HBPM devices is not commonly reimbursed by insurance 
companies (5, 72). Therefore, HBPM may be inaccessible to low income individuals. Some 
devices do not record blood pressure readings leading to reliance on the patient to document 
their blood pressure measurements (73). HBPM requires a long-term commitment from 
patients in taking their blood pressure over days, weeks or even longer periods, which may 
be challenging for many patients. Physicians are concerned about the use of non-validated 
HBPM devices, lack of knowledge of where to purchase validated devices, lack of 
established measurement protocols, and the patient’s preoccupation with his or her own 
blood pressure, which may lead to anxiety (74-78). Additional issues relate to the lack of 
proper training of the patient in HBPM procedures (75). Patients with hypertension may not 
have access to adjunctive strategies for HBPM such as one-to-one counseling, remote 
telemonitoring, and educational classes, which may be essential for achieving and 
maintaining blood pressure control while using HBPM (72, 79).
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Clinical Core Competency Requirements for the Conduct of ABPM and 
HBPM
Clinical core competency requirements for the conduct of ABPM and HBPM do not exist in 
the US. Appendix Table 3 (available at www.annals.org) includes proposed clinical core 
competency requirements for ABPM and HBPM with an emphasis on increasing medical 
knowledge and improving patient care and procedural skills. Three areas need further 
development: structured training in the use of ABPM and HBPM, tests evaluating proof of 
competence, and requirements for maintenance of competence. Training for the proposed 
clinical core competency requirements could take place during medical school clerkships, 
residency or fellowship training for physicians, and during professional programs for other 
practitioners (e.g. nurses, nurse practitioners, etc.). Workshops or conferences on ABPM and 
HBPM could also play a role in training practicing physicians or other practitioners. 
Documentation of ABPM and possibly HBPM competence could be achieved by 
successfully passing an exam, and the implementation and interpretation of a minimum 
number of ABPM and HBPM procedures. Maintenance of competence should require 
ongoing continuing medical education and conduct of a minimum number of ABPM and 
HBPM recordings annually.
Important Knowledge Gaps and Future Directions
A number of clinically relevant questions remain unanswered. Studies are needed to 
determine whether using mean blood pressure from ABPM or HBPM to guide 
antihypertensive medication initiation and titration leads to a reduction in clinical outcomes 
compared with using clinic blood pressure alone (80, 81). Scarce information is available on 
the CVD risk reduction benefits of treating ABPM or HBPM phenotypes (e.g. non-dipping 
blood pressure) besides mean out-of-clinic blood pressure. There are few data on the 
mechanisms underlying ABPM and HBPM phenotypes, which may help identify treatment 
targets. There are many newer devices or technologies, which hold promise for the 
assessment of out-of-clinic blood pressure, but they require further evaluation in rigorous 
studies. Devices worn on the wrist, which are less burdensome to patients, may have broad 
appeal. These devices are currently not recommended for routine clinical use as some 
studies indicate the presence of a systematic error when compared with upper arm 
measurements (2, 82). These devices may benefit individuals with a large arm 
circumference in whom upper arm devices may provide an inaccurate reading (2). Another 
emerging area is self-measurement devices that are linked to mobile health applications that 
allow individuals to monitor and manage their own blood pressure (83, 84). Validating these 
methods for assessing out-of-clinic blood pressure is important given the widespread 
availability of mobile technology.
Conclusions
Evidence has accumulated over the past several decades that mean out-of-clinic blood 
pressure measured by ABPM and HBPM maintains a stronger association with CVD and 
mortality risk than clinic blood pressure. Given the high prevalence of white coat 
hypertension and its benign prognosis in most observational studies, it may be reasonable to 
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use ABPM and secondarily HBPM to identify white coat hypertension in untreated 
individuals with elevated clinic blood pressure. Data on the prognostic value of using 
ABPM or HBPM compared to clinic blood pressure in guiding antihypertensive medication 
use and titration are needed. There are limited data on using ABPM or HBPM to identify 
and treat blood pressure phenotypes other than white coat hypertension. Randomized 
controlled trials of ABPM and HBPM on outcomes are needed to address these knowledge 
gaps. Interventions that address barriers to ABPM and HBPM will also help translate the 
large body of research on ABPM and HBPM into clinical practice.
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• ABPM assesses blood pressure during routine daily activities typically during 
one 24-hour period, whereas HBPM assesses blood pressure at specific times 
during the day and night over a longer period of time while the patient is seated 
and resting.
• Blood pressure measures on ABPM and HBPM have a stronger association with 
CVD outcomes than clinic blood pressure.
• ABPM and HBPM can quantify mean out-of-clinic blood pressure and can be 
used to identify white coat hypertension, masked hypertension, blood pressure 
variability, and hypotension. ABPM can also assess nighttime blood pressure 
and diurnal blood pressure patterns.
• Most guidelines, scientific statements, and position papers recommend that out-
of-clinic blood pressure monitoring be primarily undertaken using ABPM to 
rule out white coat hypertension in individuals with elevated clinic blood 
pressure. HBPM is recommended if ABPM is not available or poorly tolerated 
by the patient.
• Barriers exist which have limited the implementation of ABPM and HBPM in 
clinical practice. Core competency requirements may be essential for the 
successful conduct of ABPM and HBPM.
• There is a need for randomized controlled trials to test whether treating blood 
pressure determined by ABPM or HBPM is more advantageous than treating 
clinic blood pressure on CVD outcomes.
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Blood pressure data from an untreated healthy individual who underwent clinic blood 
pressure assessment immediately followed by 24-hour ABPM (upper panel). HBPM was 
then performed for 18 days (lower panel). The points for clinic blood pressure represent the 
average of 3 readings. The points on HBPM represent the average of 2 morning or 2 evening 
readings. Average clinic blood pressure, daytime (awake), nighttime (sleep), 24-hour blood 
pressure, and home blood pressure are shown in the figure. On ABPM (upper panel), blood 
pressure falls to its lowest level during at night, followed by a surge in the morning hours 
coinciding with waking up. Because blood pressure readings on HBPM (lower panel) are 
obtained at fixed times during the day, and are measured at rest, the variability of blood 
pressure over time is less than what is observed on ABPM. Unlike ABPM, HBPM cannot 
measure blood pressure readings during sleep. Abbreviations: ABPM = ambulatory blood 
pressure monitoring. BP = blood pressure. DBP = diastolic blood pressure. HBPM = home 
blood pressure monitoring. SBP = systolic blood pressure.
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Table 1
Blood pressure thresholds for ambulatory blood pressure monitoring (top panel) and home blood pressure 
monitoring (bottom panel) recommended by different scientific societies
Recommended systolic/diastolic blood pressure thresholds for ABPM
2005 AHA Scientific Statement (1)
Optimal Normal Elevated
Daytime <130/80 mmHg <135/85 mmHg >140/90 mmHg
Nighttime <115/65 mmHg <120/70 mmHg >125/75 mmHg
24-hour <125/75 mmHg <130/80 mmHg >135/85 mmHg
2005 ESH Practice Guidelines (37)
Optimal Normal Elevated
Daytime <130/80 mmHg <135/85 mmHg >140/90 mmHg
Nighttime <115/65 mmHg <120/70 mmHg >125/75 mmHg
24-hour -- -- --
2008 ASH Position Paper (38)
Optimal Normal Elevated
Daytime -- -- ≥135/85 mmHg
Nighttime -- -- ≥120/75 mmHg
24-hour -- -- ≥130/80 mmHg
2013 ESH Position Paper (4)
Optimal Normal Elevated
Daytime -- -- ≥135/85 mmHg
Nighttime -- -- ≥120/70 mmHg
24-hour -- -- ≥130/80 mmHg
Recommended systolic/diastolic blood pressure thresholds for HBPM
2008 AHA/ASH/PCNA Call to Action (5)
Normal Elevated
-- ≥135/85 mmHg
2008 ASH Position Paper (38)
Normal Elevated
-- ≥135/85 mmHg
2010 ESH Guidelines (39)
Normal Elevated
<130/80 mmHg ≥135/85 mmHg
2013 ESH/ESC Guidelines (2)
Normal Elevated
-- ≥135/85 mmHg
The different guidelines, position papers, and scientific statements use terms like “abnormal”, “limit”, “threshold”, “goal”, “hypertension”, or 
“elevated” to designate when a diagnosis of hypertension is made or when treatment should be titrated. In this table, we use the term “elevated”.
-- Thresholds were not reported.
AHA = American Heart Association
AHA/ASH/PCNA = American Heart Association/ American Society of Hypertension/Preventive Cardiovascular Nurses Association
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ASH = American Society of Hypertension
ESH = European Society of Hypertension
ESH/ESC = European Society of Hypertension/European Society of Cardiology
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Table 2
Phenotypes defined by clinic and out-of-clinic hypertension status.




No Sustained Normotension Masked Hypertension
Yes* White Coat Hypertension Sustained Hypertension
*
Mean systolic/diastolic blood pressure ≥140/90 mmHg based on clinic measurements.
†Commonly, mean daytime (or home) systolic/diastolic blood pressure ≥135/85 mmHg based on ambulatory blood pressure monitoring (or home 
blood pressure monitoring).
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